Session » Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1311

A Multidisciplinary Cohort of Patients with Interstitial Pneumonia with Autoimmune Features

9:00AM-11:00AM: Abstract Number: 1320

Activity Tracker Bracelets Captures Familial Mediterranean Fever Attacks and Their Impact on Daily Physical Activities

9:00AM-11:00AM: Abstract Number: 1324

Anakinra Treatment in Refractory Cases of Adult-Onset Still Disease: Case Series

9:00AM-11:00AM: Abstract Number: 1314

Autoantibodies and Clinical Outcomes in Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases

9:00AM-11:00AM: Abstract Number: 1307

Autoantibodies in Idiopathic Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features – a Prospective Study

9:00AM-11:00AM: Abstract Number: 1325

Canakinumab Treatment in Adult-Onset Still’s Disease: Case Series

9:00AM-11:00AM: Abstract Number: 1321

Clinical and Genetic Analysis of the Patients Mimicking Familial Mediterranean Fever

9:00AM-11:00AM: Abstract Number: 1306

Clinical Characteristics and Treatment Patterns in Patients with Interstitial Pneumonia with Autoimmune Features (IPAF)

9:00AM-11:00AM: Abstract Number: 1313

Clinical Features and Timing of Studies in Interstitial Lung Disease with Autoimmune Disease Features: Do Autoantibody Panels Improve Diagnostic Yields and/or Increase Costs?

9:00AM-11:00AM: Abstract Number: 1318

Clinical Utility of Ultrasonography (US) in Diagnosing and Monitoring Disease Activity of Relapsing Polychondritis (RP) and Comparison of Cartilaginous US Findings between RP, Repeated Trauma and Healthy Subjects

9:00AM-11:00AM: Abstract Number: 1329

Combination of Methotrexate and Leflunomide in Refractory Chronic Adult Onset Still’s Disease: Case Series and Literature Review

9:00AM-11:00AM: Abstract Number: 1322

Comparison of Serum Hepcidin and Calprotectin Levels in Patients with Familial Mediterranean Fever (FMF) and Healthy Subjects

9:00AM-11:00AM: Abstract Number: 1310

Diagnostic Utility of Myositis Antibodies in Patients with Interstitial Lung Disease and Suspected Underlying Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1326

Does Testing for SAA Is More Beneficial Than CRP for the Follow-up of Patients with Familial Mediterranean Fever ?

9:00AM-11:00AM: Abstract Number: 1330

Dyskeratotic Cells in Persistent Pruritic Skin Lesions Are Apoptotic and Associated with High Levels of Serum IL-18, and Possibly Predict the Outcomes in Adult-Onset Still’s Disease

9:00AM-11:00AM: Abstract Number: 1308

Efficacy of Rituximab for Connective Tissue Disease (CTD) Associated Interstitial Lung Disease (ILD):a Single Center Study of 47 Patients

9:00AM-11:00AM: Abstract Number: 1323

Evaluation of Prolidase and HIF-1α Levels in Patients with Familial Mediterranean Fever (FMF)

9:00AM-11:00AM: Abstract Number: 1319

Familial Mediterranean Fever Related Damage Assessed By Auto-Inflammatory Disease Damage Index (ADDI) and Associated Factors with Damage

9:00AM-11:00AM: Abstract Number: 1312

Interstitial Pneumonia with Autoimmune Features (IPAF)-Nsip: Hurdles to Reclassification of Overlapping Ilds

9:00AM-11:00AM: Abstract Number: 1309

Interstitial Pneumonia with Autoimmune Features: Is It Frequent?

9:00AM-11:00AM: Abstract Number: 1315

Japanese Relapsing Polychondritis Patients with Airway Involvement Were Mutually Exclusive with Those with Ear Involvement in the Clinical Characteristics

9:00AM-11:00AM: Abstract Number: 1328

Recurrent Pericarditis: A Challenge in Autoinflammatory Disease Clinic and the Role of Anakinra

9:00AM-11:00AM: Abstract Number: 1316

Respiratory Involvement in Relapsing Polychondritis – a Single Centre Study

9:00AM-11:00AM: Abstract Number: 1305

Risk of Progression of Interstitial Lung Disease with Autoimmune Features to a Systemic Autoimmune Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1304

Rituximab in Connective Tissue Disease – Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1303

Rituximab Versus Mycophenolate Mofetil in Interstitial Lung Disease Secondary to Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1327

The Effect of Etoposide on Inducing Remission in Refractory Adult-Onset Still’s Disease: A Retrospective, Single-Center Study

9:00AM-11:00AM: Abstract Number: 1317

Tracheomalacia in Coventry in UK

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].